Market Overview

Lupin Says Received FDA Approval for Generic Lexapro

Related FRX
Regulatory Update from Forest Labs - Analyst Blog
Pipeline Progress at Prothena - Analyst Blog

Pharma major, Lupin Ltd., announced today that its subsidiary Lupin Pharmaceuticals Inc. (collectively, Lupin) has received final approval for its Escitalopram Tablets (Escitalopram oxalate) 5 mg, 10 mg, and 20 mg, from the United States Food and Drugs Administration (FDA) to market a generic version of Forest Laboratories, Inc.'s (Forest) Lexapro Tablets, 5 mg, 10 mg, and 20 mg.

Posted-In: News FDA

 

Most Popular

Related Articles (FRX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free